Eli Lilly and Company (LLY) - Utang jangka dawa marang modal

This chart shows the market price of Eli Lilly and Company (LLY) demonstrating a phase of exceptional growth driven by the hype surrounding weight-loss drugs, with the indicator standing at 1.24. The business relies on a massive infrastructure of plants in Europe and the US, continuously expanding its capacity. Strict regulatory requirements and costly patents guarantee profit stability, creating a long-term monopoly status for the company.

To objectively assess the stability of Eli Lilly and Company (LLY), it is essential for a manager to understand the long-term debt-to-equity ratio, which determines the company's degree of dependence on external borrowings over a long-term horizon. The dynamics of the long-term debt-to-equity ratio reflect the balance between financial leverage and shareholder value, which is critical when financing the large-scale robotization of laboratories and the digitalization of clinical trials.